Fusion Antibodies Ltd. (FAB)

Overview

Fusion Antibodies plc operates as a contract research organization focused on the research, development, and manufacture of recombinant proteins and antibodies, primarily targeting cancer and infectious diseases. Since its incorporation in 2000 and based in Belfast, United Kingdom, the company has been delivering its expertise and services across the United Kingdom, the rest of Europe, North America, and other international markets. It caters to a diverse clientele that includes pharmaceutical, biotech, veterinary, diagnostic, and life science research sectors. Fusion Antibodies plc has established a collaborative relationship with the National Cancer Institute (NCI) to utilize OptiMAL for the discovery of novel antibodies against NCI-selected targets, underlining its commitment to advancing research and development in the field of medicine.

Products and Services

• Monoclonal Antibody Discovery and Development

This service focuses on identifying and developing monoclonal antibodies for therapeutic and diagnostic use. Fusion Antibodies employs cutting-edge technologies to discover antibodies with high specificity and affinity for their target antigens, catering to the needs of the pharmaceutical and biotech industries.

• Antibody Sequencing

Fusion Antibodies offers antibody sequencing services designed to determine the precise order of amino acids in antibodies. This critical information facilitates the understanding of antibody mechanisms, supporting further antibody engineering and development efforts.

• Antibody Engineering

Through its antibody engineering services, Fusion Antibodies aims to modify natural antibodies to enhance their properties, including increased stability, reduced immunogenicity, or improved binding affinity, thus making them more effective for research or therapeutic applications.

• Antibody Humanization and Rational Affinity Maturation Platform

This service is tailored for the humanization of monoclonal antibodies derived from non-human species, making them suitable for therapeutic use in humans by reducing potential immune responses. Additionally, the rational affinity maturation platform is leveraged to enhance the binding affinity of humanized antibodies to their targets.

• Recombinant Protein Expression

Fusion Antibodies provides recombinant protein expression services, utilizing various expression systems to produce high yields of quality proteins for research, diagnostic, or therapeutic applications. This expertise ensures the delivery of proteins with the desired functionality and purity.

• Stable Cell Line Development and cGMP Scale Up Services

The company offers stable cell line development services, creating cell lines that consistently express a protein of interest, which is critical for biomanufacturing processes. Furthermore, its cGMP scale-up services ensure that these processes comply with Good Manufacturing Practices, allowing for the production of therapeutic proteins under regulatory standards.